{
  "id": "adv_mhgap#referral_fdcca283",
  "content": "breastfeeding: Avoid\nOlder adults: Use lower doses\nSODIUM VALPROATE Adults: Common: Sedation, headache, tremor, ataxia, nausea, Use with caution if underlying or suspected hepatic disease.\nStart 400 mg daily in 2 divided doses. vomiting, diarrhea, weight gain, transient hair loss.\nIncrease by 500 mg daily each week Drug-drug interactions: Valproate levels decreased by carbamazepine,\nSerious: Impaired hepatic function, thrombocytopenia,\n(maximum 3000 mg daily). increased by aspirin.\nleukopenia, drowsiness/confusion (valproate-induced\nChildren: hyperammonemic encephalopathy, a sign of toxicity),\nStart 15-20 mg/kg daily in 2-3 divided doses. liver failure, hemorrhagic pancreatitis.\nIncrease each week by 15 mg/kg daily\n(max 15-40 mg/kg daily).\nWomen who are pregnant: Avoid\nOlder adults: Use lower doses\nEPI 3 Follow-up\nRECOMMENDATIONS ON\nFREQUENCY OF CONTACT\n1 » Follow up should occur\nevery 3-6 months\nREVIEW THE CURRENT CONDITION\nDoes the person have more than 50% seizure reduction in convulsion frequency?\nIF THE PERSON IS NOT IMPROVING ON CURRENT DOSE:\n»\nReview adherence to medications.\n»\nConsider increase in medication dose as needed to\nmaximal dose if no adverse effects.\n»\nIf response is still poor,\n– Consider switching medication. The new medication\nshould be at an optimum dose before slowly discon-\ntinuing the first.\n»",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "emotions",
      "referral",
      "management"
    ],
    "is_clinical": true,
    "is_advice": true
  },
  "index_text": "General — Referral breastfeeding: Avoid\nOlder adults: Use lower doses\nSODIUM VALPROATE Adults: Common: Sedation, headache, tremor, ataxia, nausea, Use with caution if underlying or suspected hepatic disease.\nStart 400 mg daily in 2 divided doses. vomiting, diarrhea, weight gain, transient hair loss.\nIncrease by 500 mg daily each week Drug-drug interactions: Valproate levels decreased by carbamazepine,\nSerious: Impaired hepatic function, thrombocytopenia,\n(maximum 3000 mg daily). increased by aspirin.\nleukopenia, drowsiness/confusion (valproate-induced\nChildren: hyperammonemic encephalopathy, a sign of toxicity),\nStart 15-20 mg/kg daily in 2-3 divided doses. liver failure, hemorrhagic pancreatitis.\nIncrease each week by 15 mg/kg daily\n(max 15-40 mg/kg daily).\nWomen who are pregnant: Avoid\nOlder adults: Use lower doses\nEPI 3 Follow-up\nRECOMMENDATIONS ON\nFREQUENCY OF CONTACT\n1 » Follow up should occur\nevery 3-6 months\nREVIEW THE CURRENT CONDITION\nDoes the person have more than 50% seizure reduction in convulsion frequency?\nIF THE PERSON IS NOT IMPROVING ON CURRENT DOSE:\n»\nReview adherence to medications.\n»\nConsider increase in medication dose as needed to\nmaximal dose if no adverse effects.\n»\nIf response is still poor,\n– Consider switching medication. The new medication\nshould be at an optimum dose before slowly discon-\ntinuing the first.\n» Breastfeeding: avoid\nolder adults: use lower doses\nsodium valproate adults: common: sedation, headache, tremor, ataxia, nausea, use with caution if underlying or suspected hepatic disease. start 400 mg daily in 2 divided..."
}